Table 2 Prevalence of 17 comorbidities in the development and validation cohorts.
Comorbidity | Entire cohort (N = 570,716) | Development cohort (70%) (N = 399,502) | Validation cohort (30%) (N = 171,214) |
|---|---|---|---|
No comorbidity | 145,929 (25.57) | 102,046 (25.54) | 43,883 (25.63) |
Ulcer disease | 211,737 (37.1) | 148,101 (37.07) | 63,636 (37.17) |
Peripheral vascular disease | 50,688 (8.88) | 35,642 (8.92) | 15,046 (8.79) |
Mild liver disease | 137,253 (24.05) | 95,987 (24.03) | 41,266 (24.1) |
Myocardial infarct | 10,170 (1.78) | 7,129 (1.78) | 3,041 (1.78) |
Connective tissue disease | 41,225 (7.22) | 28,817 (7.21) | 12,408 (7.25) |
Congestive heart failure | 27,970 (4.9) | 19,582 (4.9) | 8,388 (4.9) |
Chronic pulmonary disease | 271,438 (47.56) | 190,206 (47.61) | 81,232 (47.44) |
Diabetes mellitus | 69,665 (12.21) | 48,668 (12.18) | 20,997 (12.26) |
Diabetes mellitus with end organ damage | 35,200 (6.17) | 24,644 (6.17) | 10,556 (6.17) |
Hemiplegia | 10,154 (1.78) | 7,132 (1.79) | 3,022 (1.77) |
Cerebrovascular disease | 63,988 (11.21) | 44,836 (11.22) | 19,152 (11.19) |
Dementia | 16,524 (2.9) | 11,580 (2.9) | 4,944 (2.89) |
Moderate or severe renal disease | 7,494 (1.31) | 5,274 (1.32) | 2,220 (1.3) |
Any tumor, leukemia, lymphoma | 39,575 (6.93) | 27,730 (6.94) | 11,845 (6.92) |
Moderate or severe liver disease | 5,334 (0.93) | 3,697 (0.93) | 1,637 (0.96) |
Metastatic solid tumor | 12,410 (2.17) | 8,664 (2.17) | 3,746 (2.19) |
AIDS | 162 (0.03) | 104 (0.03) | 58 (0.03) |
One or more comorbidity | 424,787 (74.43) | 297,456 (74.46) | 127,331 (74.37) |
